Literature DB >> 18230735

Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase.

Junpeng Deng1, Patrick A Lewis, Elisa Greggio, Eli Sluch, Alexandra Beilina, Mark R Cookson.   

Abstract

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of Parkinson's disease (PD). LRRK2 contains a Ras of complex proteins (ROC) domain that may act as a GTPase to regulate its protein kinase activity. The structure of ROC and the mechanism(s) by which it regulates kinase activity are not known. Here, we report the crystal structure of the LRRK2 ROC domain in complex with GDP-Mg(2+) at 2.0-A resolution. The structure displays a dimeric fold generated by extensive domain-swapping, resulting in a pair of active sites constructed with essential functional groups contributed from both monomers. Two PD-associated pathogenic residues, R1441 and I1371, are located at the interface of two monomers and provide exquisite interactions to stabilize the ROC dimer. The structure demonstrates that loss of stabilizing forces in the ROC dimer is likely related to decreased GTPase activity resulting from mutations at these sites. Our data suggest that the ROC domain may regulate LRRK2 kinase activity as a dimer, possibly via the C-terminal of ROC (COR) domain as a molecular hinge. The structure of the LRRK2 ROC domain also represents a signature from a previously undescribed class of GTPases from complex proteins and results may provide a unique molecular target for therapeutics in PD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230735      PMCID: PMC2234173          DOI: 10.1073/pnas.0709098105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  High resolution crystal structure of a key editosome enzyme from Trypanosoma brucei: RNA editing ligase 1.

Authors:  Junpeng Deng; Achim Schnaufer; Reza Salavati; Kenneth D Stuart; Wim G J Hol
Journal:  J Mol Biol       Date:  2004-10-22       Impact factor: 5.469

2.  Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.

Authors:  Andrew B West; Darren J Moore; Catherine Choi; Shaida A Andrabi; Xiaojie Li; Dustin Dikeman; Saskia Biskup; Zhenshui Zhang; Kah-Leong Lim; Valina L Dawson; Ted M Dawson
Journal:  Hum Mol Genet       Date:  2007-01-02       Impact factor: 6.150

3.  Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins.

Authors:  M V Milburn; L Tong; A M deVos; A Brünger; Z Yamaizumi; S Nishimura; S H Kim
Journal:  Science       Date:  1990-02-23       Impact factor: 47.728

4.  The pre-hydrolysis state of p21(ras) in complex with GTP: new insights into the role of water molecules in the GTP hydrolysis reaction of ras-like proteins.

Authors:  A J Scheidig; C Burmester; R S Goody
Journal:  Structure       Date:  1999-11-15       Impact factor: 5.006

Review 5.  G protein mechanisms: insights from structural analysis.

Authors:  S R Sprang
Journal:  Annu Rev Biochem       Date:  1997       Impact factor: 23.643

Review 6.  LRRK2 in Parkinson's disease: protein domains and functional insights.

Authors:  Ignacio F Mata; William J Wedemeyer; Matthew J Farrer; Julie P Taylor; Kathleen A Gallo
Journal:  Trends Neurosci       Date:  2006-04-17       Impact factor: 13.837

7.  The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.

Authors:  Luxuan Guo; Payal N Gandhi; Wen Wang; Robert B Petersen; Amy L Wilson-Delfosse; Shu G Chen
Journal:  Exp Cell Res       Date:  2007-07-19       Impact factor: 3.905

8.  Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.

Authors:  Berta Luzón-Toro; Elena Rubio de la Torre; Asunción Delgado; Jordi Pérez-Tur; Sabine Hilfiker
Journal:  Hum Mol Genet       Date:  2007-06-20       Impact factor: 6.150

9.  The R1441C mutation of LRRK2 disrupts GTP hydrolysis.

Authors:  Patrick A Lewis; Elisa Greggio; Alexandra Beilina; Shushant Jain; Acacia Baker; Mark R Cookson
Journal:  Biochem Biophys Res Commun       Date:  2007-04-10       Impact factor: 3.575

10.  Crystal structure of intact elongation factor EF-Tu from Escherichia coli in GDP conformation at 2.05 A resolution.

Authors:  H Song; M R Parsons; S Rowsell; G Leonard; S E Phillips
Journal:  J Mol Biol       Date:  1999-01-22       Impact factor: 5.469

View more
  105 in total

1.  A CC' loop decoy peptide blocks the interaction between Act1 and IL-17RA to attenuate IL-17- and IL-25-induced inflammation.

Authors:  Caini Liu; Shadi Swaidani; Wen Qian; Zizhen Kang; Paige Sun; Yue Han; Chenhui Wang; Muhammet Fatih Gulen; Weiguo Yin; Chunjiang Zhang; Paul L Fox; Mark Aronica; Thomas A Hamilton; Saurav Misra; Junpeng Deng; Xiaoxia Li
Journal:  Sci Signal       Date:  2011-11-01       Impact factor: 8.192

2.  GTP-binding protein-like domain of AGAP1 is protein binding site that allosterically regulates ArfGAP protein catalytic activity.

Authors:  Ruibai Luo; Itoro O Akpan; Ryo Hayashi; Marek Sramko; Valarie Barr; Yoko Shiba; Paul A Randazzo
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

Review 3.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

4.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.

Authors:  Veronique Daniëls; Renée Vancraenenbroeck; Bernard M H Law; Elisa Greggio; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Mark R Cookson; Kirsten Harvey; Veerle Baekelandt; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

5.  The structural basis for the sensing and binding of cyclic di-GMP by STING.

Authors:  Yi-He Huang; Xiang-Yu Liu; Xiao-Xia Du; Zheng-Fan Jiang; Xiao-Dong Su
Journal:  Nat Struct Mol Biol       Date:  2012-06-24       Impact factor: 15.369

6.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

7.  Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.

Authors:  Giambattista Guaitoli; Francesco Raimondi; Bernd K Gilsbach; Yacob Gómez-Llorente; Egon Deyaert; Fabiana Renzi; Xianting Li; Adam Schaffner; Pravin Kumar Ankush Jagtap; Karsten Boldt; Felix von Zweydorf; Katja Gotthardt; Donald D Lorimer; Zhenyu Yue; Alex Burgin; Nebojsa Janjic; Michael Sattler; Wim Versées; Marius Ueffing; Iban Ubarretxena-Belandia; Arjan Kortholt; Christian Johannes Gloeckner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-29       Impact factor: 11.205

Review 8.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

Review 9.  Role of LRRK2 kinase dysfunction in Parkinson disease.

Authors:  Azad Kumar; Mark R Cookson
Journal:  Expert Rev Mol Med       Date:  2011-06-13       Impact factor: 5.600

10.  LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.

Authors:  Loukia Parisiadou; Jia Yu; Carmelo Sgobio; Chengsong Xie; Guoxiang Liu; Lixin Sun; Xing-Long Gu; Xian Lin; Nicole A Crowley; David M Lovinger; Huaibin Cai
Journal:  Nat Neurosci       Date:  2014-01-26       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.